Evaluation of Indication-Based Pricing for Oncology Biologic
Evaluated potential strategies to implement Indication Based Pricing (IBP) and understand the impact to ASP and other reimbursement/payment metrics surrounding an oncology biologic.
Evaluated potential strategies to implement Indication Based Pricing (IBP) and understand the impact to ASP and other reimbursement/payment metrics surrounding an oncology biologic. ADVI did this by identifying key operational issues related to implementing IBP and quantitatively modeling the impact of discounting to product ASP.
CEO insights
Related articles
Real analysis from people who’ve been there
CMMI Engagement on CGT Model
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat.
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.